Co-Diagnostics
CODX
4 hedge funds and large institutions have $919K invested in Co-Diagnostics in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.04% more ownership
Funds ownership: 0% → 0.04% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$388K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$351K |
| 3 |
Morgan Stanley
New York
|
+$7.79K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.68K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Millennium Management
New York
| $477K | +$388K | +2,542 | New |
|
|
2
HighTower Advisors
Chicago,
Illinois
| $430K | +$351K | +2,295 | New |
|
|
3
Morgan Stanley
New York
| $10K | +$7.79K | +51 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $2K | +$1.68K | +11 | New |
|
CODX Hedge Fund Activity: Q3 2017 in Review
4 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q3 2017, worth a combined $919K.
Buyers outnumbered sellers: 4 funds opened new CODX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $388K.
- 4 institutional investors held Co-Diagnostics (CODX) as of Q3 2017, up from 0 in Q2 2017.
- Funds reported $919K of Co-Diagnostics stock for Q3 2017.
- 4 funds opened new Co-Diagnostics positions in Q3 2017 and 0 closed out, a net change of +4 holders.
- The largest Co-Diagnostics buyer in Q3 2017 was Millennium Management, an estimated $388K added.
Based on aggregated 13F filings for Q3 2017.